The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | AML clinical trials: early stage vs. relapse/refractory patients
Clinical trials for acute myeloid leukemia (AML) typically only include relapsed/refractory patients, rather than patients at an earlier stages of the disease. Speaking from the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Marion Subklewe, MD, of the University of Munich, Munich, Germany, explains the downsides of this, but highlights the reasons why this occurs.
